effector.jpg
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent
July 22, 2021 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
effector.jpg
eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports
July 16, 2021 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, announced...
effector.jpg
eFFECTOR Therapeutics to Present at JMP Securities 2021 Life Sciences Conference
June 14, 2021 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) --  eFFECTOR Therapeutics, Inc. (“eFFECTOR”), a biopharmaceutical company focused on pioneering the development of selective translation regulation...
effector.jpg
eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial
June 09, 2021 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
effector.jpg
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies
May 27, 2021 08:00 ET | eFFECTOR Therapeutics
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical...
effector.jpg
eFFECTOR and Quantitative Biosciences Institute (QBI) at UCSF Receive $5.0 Million from DARPA to Evaluate Zotatifin in COVID-19
May 04, 2021 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today...
effector.jpg
eFFECTOR Appoints Mike Byrnes as Chief Financial Officer
January 07, 2021 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
effector.jpg
eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer® (SU2C) Canada
November 12, 2020 08:12 ET | eFFECTOR Therapeutics
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
effector.jpg
eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities
October 26, 2020 16:05 ET | eFFECTOR Therapeutics
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
effector.jpg
eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer
October 15, 2020 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today...